A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma

Hugo J. A. Adams*, Thomas C. Kwee

*Corresponding author for this work

Research output: Contribution to journalLetterAcademicpeer-review

2 Citations (Scopus)
32 Downloads (Pure)
Original languageEnglish
Pages (from-to)852-854
Number of pages3
JournalJournal of Clinical Oncology
Volume37
Issue number10
DOIs
Publication statusPublished - 1-Apr-2019

Keywords

  • RESPONSE ASSESSMENT
  • INTERIM

Cite this